The US Biosimilar Market: Stunted Growth and Possible Reforms

The US biosimilar market has experienced limited growth since the 2010 creation of an abbreviated approval pathway, with only 13 FDA approvals and 6 products actually available to patients as of November 2018, due to manufacturing, regulatory, and marketing barriers. The authors recommend reforms to address these obstacles and accelerate biosimilar market entry and adoption.